Navigation Links
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
Date:12/3/2008

vailable via a link in the Investor section at http://investor.sangamo.com/index.cfm under "Events and Presentations".

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform to specific human disease as well as plant agriculture, high value research reagents and cell-line engineering, clinical tria
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
7. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Moms are ready to live the "measured life" ... kids, according to the results of the BabyCenter® U.S. ... for Moms, the latest installment in BabyCenter,s 21 st ... and parenting web and mobile destination worldwide, conducted the ... say they can,t think of a reason not to ...
(Date:10/22/2014)... 22, 2014 AVACEN Medical announced today that ... (k) OTC clearance by the U.S. Food and Drug ... marketed over the Internet for: the temporary relief ... minor strains and sprains . Logo - ... (MSRP $2495) is a sophisticated medical device incorporating over ...
(Date:10/22/2014)... , Oct. 22, 2014  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... and Chief Executive Officer, has been elected to the ... Steven G. Anderson , Executive Chairman of ... proven to be an excellent leader who is well ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
... A new report criticizes the US Drug Enforcement ... addictive medications without a valid prescription requirement. ... , analyzes the DEA,s implementation of the Ryan Haight Online ... named after an 18-year old who died after purchasing Vicodin ...
... VIEW, Calif., June 8, 2011 Edison Pharmaceuticals, ... Drug Administration has granted orphan drug designation to ... diseases. Today, these mitochondrial diseases affect an estimated ... passed in 1982, provides incentives for companies to ...
Cached Medicine Technology:Report Criticizes DEA for Failing to Address Online Pharmacy Problem 2Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation 2
(Date:10/22/2014)... Amy Norton HealthDay ... Headlines remain riveted on the three Ebola cases in Dallas. ... bigger health threat to Americans. President Barack Obama on ... to the virus, which has infected two Dallas nurses who ... month at Texas Health Presbyterian Hospital. But the U.S. ...
(Date:10/22/2014)... October 22, 2014 Shriners Hospitals for ... will change the current location of Shriners Hospitals for ... Limestone across from the University of Kentucky Albert B. ... ambulatory care center, owned and operated by Shriners Hospitals ... needs of children and their families well into the ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... Grants Pass, OR (PRWEB) October 22, 2014 ... while Southern California’s fresh water supply runs dangerously low, ... climate change. Southern Oregon’s rivers, despite the lowest mountain ... fast even in late summer and early autumn.* That ... Urness, authors of the new book “Hiking Southern Oregon,” ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
... MOORESVILLE, N.C., Sept. 2 Anpath Group, Inc. (OTC Bulletin Board: ... has joined the Board of Directors. , , ... disease care, specifically with HIV treatment and immunology. Currently he ... American Academy of HIV Medicine. In 2000, he founded his ...
... , THE WOODLANDS, Texas, Sept. 2 eCardio ... America,s fastest-growing private companies - the Inc. 500. Inc. magazine ... top quarter as #117 with a three-year sales growth of 1,424%. ... going to change the world, look at the Inc. 500," said Inc. ...
... , , , BARCELONA, Spain, ... drug-drug interactions, versus other statins, as evidenced by a new study ... pharmacokinetics of LIVALO in healthy volunteers. The data were presented by ... Spain. , , Many statins currently prescribed in ...
... , Agreement Will Advance Research Connecting ... , MORGANTOWN, W.V., Sept. 2 The ... a group of neurological specialists (Brain Injury Group) to examine ... trauma, and strokes and BRNI,s research. Together, they will explore ...
... LONDON, Sept. 2 Although most hospitals in Europe ... have a fully integrated and functional hospital information systems (HIS) ... in Europe varied from about 73.0 per cent in Italy ... pressures on the government and regulatory authorities to garner more ...
... , ... the Convenience of Desktop Fax and Print-to-Fax Capabilities to Epygi,s SMB and Small/Medium Enterprise ... ... Technologies, Ltd., a worldwide provider of small to medium business IP PBX telephone systems, ...
Cached Medicine News:Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 2Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 3Health News:eCardio Included on Inc. Magazine's 28th Annual List of America's Fastest-Growing Private Companies -- the Inc. 500 2Health News:Study Shows LIVALO(R) is not Affected by Co-Administration of Itraconazole 2Health News:Study Shows LIVALO(R) is not Affected by Co-Administration of Itraconazole 3Health News:Study Shows LIVALO(R) is not Affected by Co-Administration of Itraconazole 4Health News:Study Shows LIVALO(R) is not Affected by Co-Administration of Itraconazole 5Health News:Blanchette Rockefeller Neurosciences Institute to Collaborate with Top Brain Injury Group 2Health News:Blanchette Rockefeller Neurosciences Institute to Collaborate with Top Brain Injury Group 3Health News:Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & Sullivan 2Health News:Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & Sullivan 3Health News:Epygi Technologies Partners with FaxBack to Incorporate Microsoft Fax into Epygi's VoIP Phone Systems 2Health News:Epygi Technologies Partners with FaxBack to Incorporate Microsoft Fax into Epygi's VoIP Phone Systems 3Health News:Epygi Technologies Partners with FaxBack to Incorporate Microsoft Fax into Epygi's VoIP Phone Systems 4
... patients with a diseased heart, the only therapy solution ... transplant. However, donor organs are not always readily available. ... are on the waiting list for a donor organ. ... save the life of a patient. On the one ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
... The Nichols Advantage® 25-Hydroxyvitamin D Assay is ... Specialty System. The Nichols Advantage® 25-Hydroxyvitamin D ... of 25-,hydroxyvitamin D (25-OH-D) and other hydroxylated ... plasma to be used as an aid ...
... The CoaguChek Pro is a ... of the coagulation parameters PT, APTT, ... professional use in hospitals and medical ... e.g., in cardiac catheterization laboratories, and ...
Medicine Products: